2. Cleveland Clinic Heart and Vascular Institute, Cleveland, Ohio, United States
3. Massachusetts General Hospital, Cardiology, Boston, United States
4. Department of Medicine, University of Florida, Gainesville, Florida, United States
5. Division of Cardiology, University of Florida, Gainesville, Florida, United States
6. Escola Paulista de Medicina - Universidade Federal de São Paulo, Brazil
As a public service to our readership, this article - peer reviewed by the Editors of EuroIntervention - has been published immediately upon acceptance as it was received. The content of this article is the sole responsibility of the authors, and not that of the journal or its publishers.
Please note that supplementary movies are not available online at this stage. Once a paper is published in its edited and formatted form, it will be accompanied online by any supplementary movies.
To read the full content of this article, please log in to download the PDF.
Methods and results: A systematic search of major electronic databases was conducted, for studies relevant to patients with failed bioprosthetic aortic valves undergoing VIV-TAVR. The primary outcome was procedural success. A total of 5,553 patients from 24 studies were included. The mean Society of Thoracic Surgery (STS) score was 7.84 +/- 5.14. The procedural success rate was high (97 %, 95% confidence interval [CI]: 94 – 98%). At 30-day, of all-cause mortality was 5% (95% CI: 3 – 6%), stroke 2% (95% CI: 1 – 2%), myocardial infarction 1% (95% CI: 1 – 2%), permanent pacemaker placement 6% (95% CI: 5 – 8%), and aortic regurgitation 7% (95% CI: 5 – 10%) at 30-days. At 1-year, incidence of all-cause mortality was 12% (95% CI: 10 – 14%), stroke 3% (95% CI: 2 – 4%), myocardial infarction 1% (95% CI: 0 – 2%), and permanent pacemaker placement 7% (95% CI: 5 – 11%). At three years, the incidence of all-cause mortality was 29% (95% CI: 25 – 34%) and stroke 6% (95% CI: 5 – 9%).
Conclusions: VIV-TAVR appears to be associated with high procedural success rates and low adverse outcomes during the short and mid-term follow-up period.
Sign in to read and download the full articleForgot your password?
Join us for free and access thousands of articles from EuroIntervention, as well as presentations, videos, cases from PCRonline.com